



## Complete Summary

---

### GUIDELINE TITLE

Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review).

### BIBLIOGRAPHIC SOURCE(S)

Riviello JJ Jr, Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, Morton LD, Phillips S, Sloan E, Shinnar S, American Academy of Neurology Subcommittee, Practice Committee of the Child Neurology Society. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2006 Nov 14;67(9):1542-50. [64 references] [PubMed](#)

### GUIDELINE STATUS

This is the current release of the guideline.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Status epilepticus

### GUIDELINE CATEGORY

Diagnosis  
Evaluation

### CLINICAL SPECIALTY

Neurology  
Pediatrics

## **INTENDED USERS**

Physicians

## **GUIDELINE OBJECTIVE(S)**

To review evidence on the assessment of the child with status epilepticus (SE)

## **TARGET POPULATION**

Children and adolescents (age 1 month to 19 years) with status epilepticus

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Diagnostic Assessment**

1. Blood cultures (considered, but not routinely recommended)
2. Lumbar puncture (considered, but not routinely recommended)
3. Blood antiepileptic drug levels
4. Toxicology testing
5. Testing for inborn errors of metabolism
6. Genetic testing (considered, but not routinely recommended)
7. Electroencephalography
8. Computed tomography
9. Magnetic resonance imaging

## **MAJOR OUTCOMES CONSIDERED**

Diagnostic yield of the data:

- Incidence of positive blood cultures
- Incidence of central nervous system (CNS) infection
- Antiepileptic drug levels
- Incidence of toxin ingestion
- Incidence of metabolic disorders
- Differential diagnosis of generalized or focal convulsive status epilepticus (SE), nonconvulsive SE, and pseudoseizures
- Incidence of structural CNS lesions found on neuroimaging

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

## **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

A literature search was conducted through the library of the University of Minnesota, and MEDLINE, for English-language articles from 1970 to 2005 and yielded 1,609 articles. The search terms were as follows: status epilepticus (SE) and, children and, magnetic resonance imaging (MRI), cranial computed tomography (CT) scan, lumbar puncture, spinal tap, electrolytes, metabolic studies, inborn errors of metabolism, electroencephalogram (EEG), hyponatremia, hypokalemia, hypocalcemia, hypoglycemia, acidosis, alkalosis, azotemia, hypophosphatemia, hypomagnesemia, pleocytosis, toxicology, intoxication. Seizures occurring in neonates less than 1 month of age were excluded, as these are defined as neonatal seizures and are different in cause and prognosis. The upper age limit was 19 years. Only articles reporting studies with more than 20 patients were included in this review. Articles consisting of single patient case reports or small samples of unusual pathologic findings, that would have biased the analysis, or articles that referred specifically to febrile or refractory SE, were excluded. Febrile SE and refractory SE were excluded because each is a selected population. Twenty-five articles were identified and reviewed for preparation of this Parameter. Relevant position papers from professional organizations were also reviewed.

Individual committee members reviewed titles and abstracts for content and relevance. Those papers dealing with diagnostic assessments of SE were selected for further detailed review. Bibliographies of the articles cited were checked for additional pertinent references.

## **NUMBER OF SOURCE DOCUMENTS**

Twenty-five articles were identified and reviewed for preparation of this Parameter. Relevant position papers from professional organizations were also reviewed.

## **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

## **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

**Class I.** A statistical,<sup>1</sup> population-based<sup>2</sup> sample of patients studied at a uniform point in time (usually early) during the course of the condition. All patients undergo the intervention of interest. The outcome, if not objective,<sup>5</sup> is determined in an evaluation that is masked to the patients' clinical presentations.

**Class II.** A statistical, non-referral-clinic-based<sup>3</sup> sample of patients studied at a uniform point in time (usually early) during the course of the condition. Most (>80%) patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.

**Class III.** A selected, referral-clinic-based<sup>4</sup> sample of patients studied during the course of the condition. Some patients undergo the intervention of interest. The outcome, if not objective,<sup>5</sup> is determined in an evaluation by someone other than the treating physician.

**Class IV.** Expert opinion, case reports or any study not meeting criteria for class I to III.

Notes: (1) Statistical sample: a complete (consecutive), random or systematic (e.g., every third patient) sample of the available population with the disease; (2) Population-based: The available population for the study consists of all patients within a defined geographic region; (3) Non-referral-clinic-based: The available population for the study consists of all patients presenting to a primary care setting with the condition; (4) Referral-clinic-based: The available population for the study consists of all patients referred to a tertiary care or specialty setting. These patients may have been selected for more severe or unusual forms of the condition and thus may be less representative; (5) Objective: An outcome measure that is very unlikely to be affected by an observer's expectations (e.g., determination of death, the presence of a mass on head computed tomography [CT], serum B12 assays).

## **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review with Evidence Tables

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Each of the selected articles was reviewed, abstracted, and classified by at least two committee members. Abstracted data included the number of patients, total episodes of status epilepticus (SE) (if given), ages, nature of subject selection, case-finding methods (prospective, retrospective, or referral), inclusion and exclusion criteria, classification, etiology, and the results of laboratory, electroencephalogram (EEG), or neuroimaging tests. A four-tiered classification scheme for determining the validity of studies on yield of established diagnostic and screening tests developed by the Quality Standards Subcommittee was utilized as part of this assessment. Depending on the strength of this evidence, it was decided whether specific recommendations could be made, and if so, the level of strength of these recommendations. Evidence pertinent to each diagnostic test together with the committee's evidence-based recommendations is presented.

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

## **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Recommendations included in this Parameter were based on review of data regarding the following tests for children presenting in status epilepticus (SE): 1) blood culture and lumbar puncture (LP) studies; 2) antiepileptic drug (AED) levels; 3) toxicology screening; 4) metabolic and genetic studies; 5)

electroencephalogram (EEG); and 6) neuroimaging including computed tomography (CT) and magnetic resonance imaging (MRI).

Most available literature did not specify whether the diagnostic tests analyzed were uniformly applied during each SE episode. Therefore, where reported data were missing, a minimum diagnostic yield for each test was calculated by dividing the total number of positive diagnostic tests reported by the total number of reported SE episodes from each study (therefore assuming that each diagnostic test was performed for each episode of SE, likely leading to an underestimate of the true diagnostic yield of these tests).

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

**A** = Established as effective, ineffective, or harmful for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)

**B** = Probably effective, ineffective, or harmful for the given condition in the specified population. (Level B rating requires at least one Class I study or at least two consistent Class II studies.)

**C** = Possibly effective, ineffective, or harmful for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)

**U** = Data inadequate or conflicting; given current knowledge, test is unproven.

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Drafts of the guideline have been reviewed by at least three American Academy of Neurology (AAN) committees, a network of neurologists, *Neurology* peer reviewers, and representatives from related fields.

# **RECOMMENDATIONS**

## **MAJOR RECOMMENDATIONS**

Definitions of the strength of the recommendations (A, B, C, U) and classification of the evidence (Class I through Class IV) are provided at the end of the "Major Recommendations" field.

## **Laboratory Studies**

### **Should Blood Cultures and Lumbar Puncture (LP) Be Routinely Done in Children with Status Epilepticus (SE)?**

#### *Recommendations*

1. There are insufficient data to support or refute whether blood cultures should be done on a routine basis in children in whom there is no clinical suspicion of infection (**Level U**).
2. There are insufficient data to support or refute whether LP should be done on a routine basis in children in whom there is no clinical suspicion of a central nervous system (CNS) infection (**Level U**).

### **Should AED Levels Be Routinely Obtained in Children Taking AEDs Who Develop SE?**

#### *Recommendation*

1. AED levels should be considered when a child with epilepsy on AED prophylaxis develops SE (**Level B, class II and III evidence**).

### **Should Toxicology Testing Be Routinely Ordered in Children with SE?**

#### *Recommendation*

1. Toxicology testing may be considered in children with SE, when no apparent etiology is immediately identified, as the frequency of ingestion as a diagnosis was at least 3.6% (**Level C, class III evidence**). To detect a specific ingestion, suspected because of the clinical history, it should be noted that a specific serum toxicology level is required, rather than simply urine toxicology screening.

## **Metabolic and Genetic Testing**

### **Should Testing for Inborn Errors of Metabolism or Genetic (Chromosomal or Molecular) Studies Be Routinely Ordered in Children with SE?**

#### *Recommendations*

1. Studies for inborn errors of metabolism may be considered when the initial evaluation reveals no etiology, especially if there is a preceding history suggestive of a metabolic disorder (**Level C, class III evidence**). The specific studies obtained are dependent on the history and the clinical examination. There is insufficient evidence to support or refute whether such studies should be done routinely (**Level U**).
2. There are insufficient data to support or refute whether genetic testing (chromosomal or molecular studies) should be done routinely in children with SE (**Level U**).

## **Electroencephalography (EEG)**

## **Should an EEG Be Routinely Performed in the Evaluation of a Child with SE?**

### *Recommendations*

1. An EEG may be considered in a child presenting with new onset SE as it may determine whether there are focal or generalized abnormalities that may influence diagnostic and treatment decisions (**Level C, class III evidence**).
2. Although nonconvulsive SE (NCSE) occurs in children who present with SE, there are insufficient data to support or refute recommendations regarding whether an EEG should be obtained to establish this diagnosis (**Level U**).
3. An EEG may be considered in a child presenting with SE if the diagnosis of pseudostatus epilepticus is suspected (**Level C, class III evidence**).

## **Neuroimaging**

### **Should Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Be Performed in Children with SE?**

#### *Recommendations*

1. Neuroimaging may be considered for the evaluation of the child with SE if there are clinical indications or if the etiology is unknown (**Level C, class III evidence**). If neuroimaging is done, it should only be done after the child is appropriately stabilized and the seizure activity controlled.
2. There is insufficient evidence to support or refute recommending routine neuroimaging (**Level U**).

## **Definitions:**

### **Classification Scheme for Determining the Yield of Established Diagnostic and Screening Tests**

**Class I.** A statistical,<sup>1</sup> population-based<sup>2</sup> sample of patients studied at a uniform point in time (usually early) during the course of the condition. All patients undergo the intervention of interest. The outcome, if not objective,<sup>5</sup> is determined in an evaluation that is masked to the patients' clinical presentations.

**Class II.** A statistical, non-referral-clinic-based<sup>3</sup> sample of patients studied at a uniform point in time (usually early) during the course of the condition. Most (>80%) patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.

**Class III.** A selected, referral-clinic-based<sup>4</sup> sample of patients studied during the course of the condition. Some patients undergo the intervention of interest. The outcome, if not objective,<sup>5</sup> is determined in an evaluation by someone other than the treating physician.

**Class IV.** Expert opinion, case reports or any study not meeting criteria for class I to III.

Notes: (1) Statistical sample: a complete (consecutive), random or systematic (e.g., every third patient) sample of the available population with the disease; (2) Population-based: The available population for the study consists of all patients within a defined geographic region; (3) Non-referral-clinic-based: The available population for the study consists of all patients presenting to a primary care setting with the condition; (4) Referral-clinic-based: The available population for the study consists of all patients referred to a tertiary care or specialty setting. These patients may have been selected for more severe or unusual forms of the condition and thus may be less representative; (5) Objective: An outcome measure that is very unlikely to be affected by an observer's expectations (e.g., determination of death, the presence of a mass on head computed tomography [CT], serum B12 assays).

### **Strength of Recommendations**

**A** = Established as effective, ineffective, or harmful for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)

**B** = Probably effective, ineffective, or harmful for the given condition in the specified population. (Level B rating requires at least one Class I study or at least two consistent Class II studies.)

**C** = Possibly effective, ineffective, or harmful for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)

**U** = Data inadequate or conflicting; given current knowledge, test is unproven.

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate diagnostic assessment of children with status epilepticus

### **POTENTIAL HARMS**

Not stated

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

- This statement is provided as an educational service of the American Academy of Neurology (AAN). It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved.
- The classification scheme developed by the Quality Standard Subcommittee (QSS) for studies related to determining the yield of established diagnostic and screening tests or interventions and is appropriate only when the diagnostic accuracy of the test or intervention is known to be good. Additionally, the abnormality potentially identified by the screening intervention should be treatable or, should have important prognostic implications. This classification is different than others currently recommended by the QSS that have been published in recent parameters that relate to diagnostic, prognostic or therapeutic studies.
- It is now common practice to obtain a complete blood count (CBC) and chemistry profiles routinely in children presenting with status epilepticus (SE). Thus, the guideline developers did not develop evidence-based recommendations for these tests but did include in appendix 4 of the original guideline document a summary of previous studies regarding their diagnostic yield. Electrolyte (e.g., Na<sup>++</sup> or other electrolytes, Ca<sup>++</sup>, glucose) abnormalities or basic metabolic disorders were reported in an average of 6% (range 1 to 16%) of children with SE. In most studies these abnormalities were listed as the etiology. However, it was unclear whether these abnormalities were responsible for the episode of SE and if correction resulted in cessation of SE.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

### IMPLEMENTATION TOOLS

Patient Resources  
Quick Reference Guides/Physician Guides

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Living with Illness

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Riviello JJ Jr, Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, Morton LD, Phillips S, Sloan E, Shinnar S, American Academy of Neurology Subcommittee, Practice Committee of the Child Neurology Society. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2006 Nov 14;67(9):1542-50. [64 references] [PubMed](#)

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2006 Nov

### GUIDELINE DEVELOPER(S)

American Academy of Neurology - Medical Specialty Society  
Child Neurology Society - Medical Specialty Society

### SOURCE(S) OF FUNDING

American Academy of Neurology (AAN)

### GUIDELINE COMMITTEE

Quality Standards Subcommittee  
Practice Committee of the Child Neurology Society

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

*Quality Standards Subcommittee Members:* Jacqueline French, MD, FAAN (*Co-Chair*); Gary S. Gronseth, MD (*Co-Chair*); Charles E. Argoff, MD; Stephen Ashwal, MD, FAAN (ex-officio) (facilitator); Christopher Bever, Jr., MD, MBA, FAAN; John D. England, MD, FAAN; Gary M. Franklin, MD, MPH (ex-officio); Gary H. Friday, MD, MPH, FAAN; Larry B. Goldstein, MD, FAAN; Deborah Hirtz, MD (ex-officio); Robert G. Holloway, MD, MPH, FAAN; Donald J. Iverson, MD, FAAN; Leslie A. Morrison, MD; Clifford J. Schostal, MD; David J. Thurman, MD, MPH; William J. Weiner, MD, FAAN; Samuel Wiebe, MD

*CNS Practice Committee Members:* Carmela Tardo, MD (*Chair*); Bruce Cohen, MD (*Vice-Chair*); Diane K. Donley, MD; Bhuwan P. Garg, MD; Brian Grabert, MD; Michael Goldstein, MD; David Griesemer, MD; Edward Kovnar, MD; Augustin Legido, MD; Leslie Anne Morrison, MD; Ben Renfro, MD; Shlomo Shinnar, MD; Gerald Silverboard, MD; Russell Snyder, MD; Dean Timmons, MD; William Turk, MD; Greg Yim, MD

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

The American Academy of Neurology (AAN) is committed to producing independent, critical and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least three AAN committees, a network of neurologists, *Neurology* peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at [www.aan.com](http://www.aan.com).

## **ENDORSER(S)**

American Academy of Pediatrics - Medical Specialty Society  
American College of Emergency Physicians - Medical Specialty Society  
American Epilepsy Society - Disease Specific Society

## **GUIDELINE STATUS**

This is the current release of the guideline.

## **GUIDELINE AVAILABILITY**

Electronic copies: A list of American Academy of Neurology (AAN) guidelines, along with a link to a Portable Document Format (PDF) file for this guideline, is available at the [AAN Web site](http://www.aan.com).

Print copies: Available from the AAN Member Services Center, (800) 879-1960, or from AAN, 1080 Montreal Avenue, St. Paul, MN 55116.

## AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

- AAN guideline development process [online]. St. Paul (MN): American Academy of Neurology. Available from the [American Academy of Neurology Web site](#).
- Diagnostic assessment of the child with status epilepticus. AAN summary of evidence-based guideline for clinicians. St. Paul (MN): American Academy of Neurology. 2 p. Available in Portable Document Format (PDF) from the [AAN Web site](#). See the related QualityTool summary on the [Health Care Innovations Exchange Web site](#).

## PATIENT RESOURCES

The following is available:

- Diagnosing the cause of status epilepticus in children. AAN guideline summary for patients and their families. St. Paul (MN): American Academy of Neurology (AAN). 2 p.

Electronic copies: Available in Portable Document Format (PDF) from the [AAN Web site](#). See the related QualityTool summary on the [Health Care Innovations Exchange Web site](#).

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

## NGC STATUS

This summary was completed by ECRI Institute on May 14, 2007.

## COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is copyrighted by the American Academy of Neurology.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/22/2008

